Clinical Trial Update: REAMBERIN® 1.5% in Rehydration Therapy of Diabetic Ketoacidosis [Phase 2, Phase 3]

View source ↗

Summary

REAMBERIN 1.5% is being studied as part of a rehydration therapy for diabetic ketoacidosis in Phase 2 and Phase 3, and the trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Ketoacidosis

Drugs mentioned

• REAMBERIN 1.5%

Snippet

Sponsor: POLYSAN Scientific & Technological Pharmaceutical Company | Conditions: Diabetic Ketoacidosis | Phase 2, Phase 3 | Status: RECRUITING